1. Whole‐body diffusion‐weighted MR imaging in lymphoma surveillance. (June 2017) Authors: Rademaker, J.; Ryan, D.; Matasar, M.; Portlock, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019) Authors: Sehn, L.H.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Diefenbach, C.M.; Flinn, I.; Hong, J.Y.; Kim, W.S.; Matasar, M.; Nastoupil, L.; Schuster, S.J.; Shadman, M.; Yoon, S.S.; Bender, B.; Chu, W.; Hernandez, G.M.; Kwan, A.; McCall, B.; Sison, I.; Wang, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Batlevi, C.L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Moskowitz, A.J.; Moskowitz, C.H.; Noy, A.; Palomba, M.L.; Portlock, C.; Straus, D.; Boccomini, C.; Tucci, A.; Zelenetz, A.D.; Seshan, V.E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL). (12th June 2019) Authors: Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; Yahalom, J.; Rademaker, J.; Dogan, A.; Seshan, V.; Younes, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA. (12th June 2019) Authors: Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D.J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; Hamlin, P.; Zelenetz, A.; Matasar, M.; von Keudell, G.; Sermer, D.; Yahalom, J.; Dogan, A.; Seshan, V.; Younes, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) Authors: Kim, W.S.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Budde, L.E.; Cheah, C.; Gregory, G.P.; Hong, J.; Ku, M.; Marlton, P.; Matasar, M.; Nastoupil, L.; Panizo, C.; Sehn, L.H.; Tzachanis, D.; Chu, W.; Hernandez, M.G.; Kwan, A.; Li, C.C.; Sison, I. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY. (June 2017) Authors: Matasar, M.; Herrera, A.F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T.M.; Kim, W.S.; Bosch, F.; Radford, J.; Flowers, C.R.; Bu, L.; Hong, W.; Sehn, L.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A PHASE I TRIAL OF 19‐28Z CAR‐T CELLS POST‐HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT‐ASCT) FOR RELAPSED AND REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL). (June 2017) Authors: Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; Matasar, M.; Curran, K.; Park, J.; Sadelain, M.; Brentjens, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA. (17th June 2021) Authors: Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; Hamlin, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY. (23rd June 2022) Authors: Matasar, M.; Bartlett, N. L.; Sehn, L. H.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L. J.; Wei, M. C.; Yin, S.; To, I.; Turner, D.; Huang, H.; Min, J.; Penuel, E.; Budde, L. E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗